Form 4: Singular Genomics Systems Director Disposes of Shares and Options Following Merger
SEC Form 4 Filing
Michael J. Pellini, a director at Singular Genomics Systems, reports the disposal of common stock and stock options due to the merger agreement where shares were converted to cash and options were cancelled or converted to cash payments.
Summary
- Michael J. Pellini, a director of Singular Genomics Systems, filed a Form 4 detailing changes in beneficial ownership.
- The filing reports the disposal of 26,834 shares of common stock and 324,388 shares held indirectly through The Pellini Family Trust.
- These disposals occurred on February 21, 2025, as a result of the merger agreement between Singular Genomics Systems, Singular Genomics Parent, LLC, and Saturn Merger Sub, Inc.
- Under the merger agreement, all outstanding shares of Singular Genomics common stock were cancelled and converted into the right to receive $20.00 per share in cash.
- Additionally, Pellini disposed of several stock options with varying exercise prices, which were either cancelled for no consideration (if the exercise price was equal to or greater than $20.00) or converted into the right to receive a cash payment based on the difference between the merger consideration and the exercise price.
- The reporting person is the trustee of The Pellini Family Trust and has voting and dispositive power with respect to these shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as the document simply reports the execution of a pre-existing merger agreement.
Future Outlook
The company is being acquired and will no longer exist as a separate publicly traded entity.
Industry Context
This announcement reflects a merger and acquisition event, which is a common occurrence in the biotechnology and genomics industry as companies seek to consolidate, expand their portfolios, or gain access to new technologies.
Stakeholder Impact
- Shareholders received $20.00 per share in cash as a result of the merger.
- Option holders received cash payments for their vested options, if the exercise price was below the merger consideration.
Key Dates
| Date | Description |
|---|---|
| 12/22/2024 | Date of the Agreement and Plan of Merger |
| 02/21/2025 | Date of transaction (disposal of shares and options) |
| 05/05/2031 | Expiration date of one of the stock option grants |
| 05/26/2032 | Expiration date of one of the stock option grants |
| 05/25/2033 | Expiration date of one of the stock option grants |
| 05/29/2034 | Expiration date of one of the stock option grants |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.